A long trail of corruption cases, oversight failures, and drug-war contradictions has left the DEA with a credibility problem, even as it continues to influence how cannabis is scheduled, researched, and regulated in the United States.
Four decades of corruption scandals and an expanding global mission raise a fundamental question: Is the DEA fighting drugs, or protecting an outdated model of drug enforcement?
The Drug Enforcement Administration wants the public to believe a simple story: heroic agents battling cartels, protecting American families from deadly substances, and making communities safer. It is a compelling narrative, one the agency has sold to Congress, the public, and presidents of both parties for more than half a century.
But if we look closely at the DEA’s actual record, a different picture emerges. One where some agents have laundered millions of dollars alongside the traffickers they were supposed to target. One where corruption investigations touching dozens of people resulted in just a single government conviction. One where overseas operations have repeatedly raised questions about mission creep and weak oversight. And one where, despite vast resources and decades of authority, the overdose crisis reached catastrophic levels and remains severe even as recent data shows some improvement.
Most troubling of all for cannabis readers, this same agency continues to exert decisive influence over marijuana policy in the United States, shaping how weed is scheduled, researched, and regulated. An institution whose credibility has been repeatedly damaged by corruption scandals and weak accountability still helps decide what Americans can legally consume, prescribe, or study.
The Pattern That Won’t Go Away
Let’s start with what is documented, not what is merely suspected.
In 2021, former DEA special agent José Irizarry was sentenced to more than twelve years in federal prison for a sprawling corruption scheme. Operating primarily overseas, …
Read More
Author: Rolando García / High Times
